. Vasopressin rapidly increases phosphorylation of UT-A1 urea transporter in rat IMCDs through PKA. Am J Physiol Renal Physiol 282: F85-F90, 2002. First published August 8, 2001 10.1152/ajprenal.00054.2001.-The UT-A1 urea transporter plays an important role in maintaining the hyperosmolar milieu of the inner medulla. Vasopressin increases urea permeability in rat terminal inner medullary collecting ducts (IMCDs) within 5-10 min. To elucidate the mechanism, IMCD suspensions were radiolabeled with [ 32 P]orthophosphate. UT-A1 was immunoprecipitated and analyzed by autoradiogram and Western blot. Both the 97-and 117-kDa UT-A1 proteins were phosphorylated. Vasopressin treatment increased the phosphorylation of both UT-A1 proteins at 2 min, which peaked at 5-10 min and remained elevated for up to 30 min. There was a discernable increase in UT-A1 phosphorylation with 10 pM and a 50% increase with 10-100 nM vasopressin. 1-Desamino-8-D-arginine vasopressin (dDAVP) or 8-(4-chlorophenylthio)-cAMP (CPT-cAMP) also increased UT-A1 phosphorylation. The vasopressin-stimulated increase in UT-A1 phosphorylation was blocked by H-89 or a specific peptide inhibitor of protein kinase A. Phosphatase inhibitors (okadaic acid, calyculin) increased UT-A1 phosphorylation. We conclude that vasopressin increases UT-A1 phosphorylation via protein kinase A within 2-5 min in rat IMCDs. This suggests that phosphorylation of UT-A1 may be the mechanism by which vasopressin rapidly increases urea permeability in vivo.
THE URINE-CONCENTRATING SYSTEM is regulated primarily by vasopressin (antidiuretic hormone), which increases both osmotic water and urea permeabilities in principal cells in the kidney collecting duct. The mechanisms regulating osmotic water permeability have been extensively studied (reviewed in Ref. 15 ). Aquaporin-2 (AQP2), the vasopressin-regulated water channel, is located in the apical membrane of collecting duct principal cells. Vasopressin increases osmotic water permeability by stimulating the insertion of AQP2-containing vesicles from the subapical region into the apical membrane. After the removal of vasopressin, AQP2 is removed from the apical membrane and remains within subapical vesicles until the cell is again stimulated by vasopressin.
Vasopressin also increases facilitated urea permeability in the perfused rat terminal inner medullary collecting duct (IMCD) (19) . However, the mechanism by which vasopressin rapidly increases urea permeability is unknown. Although urea is a small molecule, it is highly polar and has a low permeability across lipid bilayers (7) . There is physiological evidence that urea transport occurs by a facilitated transport pathway in the IMCD, and several cDNAs for facilitated urea transporters have now been cloned from kidney (UT-A) and erythrocytes (UT-B) (reviewed in Ref. 18 ).
One possible mechanism by which vasopressin could increase urea permeability is regulated trafficking of UT-A1, as suggested by comparison with the mechanism by which vasopressin regulates AQP2 [AQP2 and UT-A1 have similar immunolocalization patterns and both are regulated rapidly by vasopressin (13, 16, 19) ]. However, Knepper and colleagues (8) tested for regulated trafficking of UT-A1 in the rat IMCD and showed that, in contrast to AQP2, vasopressin does not regulate UT-A1 via vesicular trafficking between the apical membrane and subapical vesicles.
The purpose of this study was to test an alternative mechanism by which vasopressin could increase urea permeability: that vasopressin, acting through cAMP, increases the phosphorylation of UT-A1 in the rat IMCD. The deduced amino acid sequence for UT-A1 contains several consensus sites for phosphorylation by protein kinase A (PKA), as well as protein kinase C or tyrosine kinase (11) . Our results indicate that UT-A1 is phosphorylated by vasopressin acting through PKA.
METHODS
IMCD suspensions. Male Sprague-Dawley rats (National Cancer Institute, Frederick, MD), weighing 200-250 g, were fed a standard rat chow, kept in filter-top cages with autoclaved bedding, and received free access to normal drinking water. Rats were injected with furosemide (5 mg ip) 20-30 min before they were killed. After death, both kidneys were rapidly removed, whole inner medullas were excised, and the tissue was transferred into microcentrifuge tubes with 1 ml of dissecting buffer containing (in mM) 118 NaCl, 2 K2HPO4, 25 NaHCO3, 1.2 MgSO4, 2 CaCl2, 5.5 glucose, and 5 sodium acetate, pH 7.4. Inner medullas were minced finely with a razor blade and put into digestion buffer containing (in mM) 118 NaCl, 5 KCl, 4 Na2HPO4, 25 NaHCO3, 2 CaCl2, 1.2 MgSO4, 5.5 glucose, and 5 sodium acetate, as well as 2 mg/ml collagenase B, 0.5 mg/ml BSA, and 540 U/ml hyaluronidase. After a 30-min incubation at 37°C, DNase I was added to a final concentration of 0.001%, and incubation was continued for another 20 min. The suspension was periodically agitated to break up large tissue fragments and to facilitate the digestion process. After the incubation, the resulting suspension was transiently (10 s) centrifuged at 50 g, the supernatant was discarded, and the pellet was resuspended in suspension buffer (digestion buffer without collagenase, BSA, or hyaluronidase). This process was repeated two additional times with suspension buffer and one time with phosphatefree DMEM (GIBCO, Grand Island, NY). The pelleted tubules were resuspended and pooled in phosphate-free DMEM; a small aliquot was removed and checked for the integrity of the tubule suspension using a dissecting microscope, and tubules were redistributed evenly into individual sample microcentrifuge tubes. In general, the two kidneys from a single rat yielded sufficient tubules for about one sample; i.e., five rats yielded sufficient tubules to compare five to seven experimental permutations.
32 P labeling. IMCD suspensions were incubated in phosphate-free DMEM containing 0.1 mCi/ml [ 32 P]orthophosphate for 3 h at 37°C and gassed with 5% CO 2-95% air. At the end of the 3-h loading period, arginine vasopressin (10 or 100 nM, Sigma, St. Louis, MO), 8-(4-chlorophenylthio)-adenosine 3Ј,5Ј-cyclic monophosphate (CPT-cAMP; 200 M, Sigma), H-89 (5 M, Calbiochem, La Jolla, CA), a specific peptide inhibitor (14O22 amide) of PKA (5 M, Calbiochem), or 1-desamino-8-D-arginine vasopressin (dDAVP; Desmopressin, 10 or 100 nM, Sigma) was added as detailed in RESULTS. Unincorporated 32 P was removed by three washes with phosphate-free DMEM. Then, the IMCDs were lysed in 1 ml RIPA buffer (10 mM Tris ⅐ HCl, pH 7.4, 2.5 mM EDTA, 50 mM NaF, 1 mM Na4P2O7 ⅐ 10H2O, 1 mM phenylmethylsulfonyl fluoride; 1% Triton X-100, 10% glycerol, 1% deoxycholate, 1 g/ml aprotinin, 0.18 mg/ml sodium orthovanadate) and sheared with a 26-gauge needle. After centrifugation at 14,000 g for 15 min to remove insoluble particulates, samples were incubated overnight with polyclonal anti-UT-A1 (12) at 4°C with gentle mixing; this antibody also detects UT-A2 and UT-A4. Immune complexes were precipitated with protein A-agarose (Pierce, Rockford, IL) for 2 h at 4°C; then, the pelleted beads were washed six times with RIPA and once with potassiumfree phosphate-buffered saline. Washes were counted to ensure complete removal of unbound radiolabeled material. Laemmli-SDS-PAGE sample buffer was added directly to the pelleted beads and boiled; proteins were size-separated on two identical SDS-polyacrylamide gels. One gel was dried, and 32 P incorporation into UT-A1 was analyzed by autoradiography. The proteins on the other gel were transferred to polyvinylidene difluoride membrane, and the amount of im- Fig. 1 . Phosphorylation of urea transporter UT-A1 is stimulated by vasopressin. Rat inner medullas were collected, and inner medullary collecting duct (IMCD) suspensions were prepared as described in METHODS. After the radiolabel was loaded, IMCDs were incubated for another 10 min with 10 Ϫ8 M vasopressin (arginine vasopressin; AVP); then, washed IMCDs were solubilized and UT-A1 was immunoprecipitated with an anti-COOH-terminal UT-A1 antibody. Left: Western blot showing equal proteins in control (ϪAVP) and vasopressin-treated (ϩAVP) samples. Right: autoradiogram of the radiolabeled UT-A1 from the same immunoprecipitated proteins. Doubleheaded arrows highlight 97-and 117-kDa UT-A1 proteins. munoprecipitated UT-A1 protein was assayed by Western blot.
Statistics. All data are presented as means Ϯ SE, and n is the number of rats. To test for the statistical significance between the results from two groups, Student's t-test or the Mann-Whitney U-test was used. To test more than two groups, ANOVA was used, followed by Tukey's protected t-test (20) to determine which groups' results were significantly different. The criterion for statistical significance was P Ͻ 0.05.
RESULTS

Effect of vasopressin.
There are two different glycosylated forms of UT-A1: 97 and 117 kDa (2) . Both the 97-and 117-kDa UT-A1 proteins are phosphorylated in the absence of any added hormone (i.e., basal phosphorylation) and exhibit increased phosphorylation on treatment with 10 Ϫ8 M vasopressin (Fig. 1) . After the addition of 10 Ϫ8 M vasopressin to the IMCD suspension, the phosphorylation of UT-A1 was significantly increased at 2 min, peaked at 5 min, and then remained increased for up to 30 min (Fig. 2) . A significant increase in UT-A1 phosphorylation was evident with 10 Ϫ11 M vasopressin, with a much larger effect with 10 Ϫ8 and 10 Ϫ7 M vasopressin (Fig. 3) . A significant increase in the phosphorylation of UT-A1 was also observed with either 10 Ϫ8 or 10 Ϫ7 M dDAVP, a selective V 2 -receptor agonist (Fig. 4) .
Role of PKA. Because vasopressin increases cAMP production in the rat terminal IMCD (21), we tested the effect of an exogenous cell-permeable cAMP analog, CPT-cAMP, and found that it significantly increased the phosphorylation of UT-A1 (Fig. 5) . Next, IMCD suspensions were treated with the PKA inhibitor H-89. H-89 significantly blocked vasopressin's stimulation of UT-A1 phosphorylation (Fig. 6 ). This result was confirmed by using the PKA inhibitor 14O22 amide, a specific, cell-permeable peptide inhibitor of PKA (Fig.  6, lanes 4 and 5, n ϭ 1) .
Next, IMCD suspensions were treated with the phosphatase inhibitors calyculin or okadaic acid. Incubation with either phosphatase inhibitor significantly increased the phosphorylation of UT-A1 (Fig. 7) . Finally, we immunoprecipitated UT-A1 from IMCD suspensions and then probed the immunoprecipitate with an anti-phosphotyrosine antibody. Although UT-A1 protein was present in the IMCD samples (Fig. 8 , center lanes, preimmunoprecipitation samples), no protein was detected when the same sample was probed with the anti-phosphotyrosine antibody (PY-20; Pharmingen/Transduction Laboratories, San Diego, CA). In addition, anti-UT-A1 did not recognize any proteins in the immunoprecipitated phosphotyrosine protein pool, and PY-20 did not recognize immunoprecipitated UT-A1. This is consistent with phosphorylation occurring in serine or threonine residues, which are the likely targets for PKA.
DISCUSSION
The major result of this study is that vasopressin, acting through PKA, increases the phosphorylation of UT-A1 in freshly isolated suspensions of rat IMCDs. The time course for vasopressin-mediated increases in UT-A1 phosphorylation matches that for vasopressinmediated increases in facilitated urea permeability in perfused rat terminal IMCDs (14, 21, 23) . These findings strongly suggest that phosphorylation of UT-A1 is a mechanism by which vasopressin increases facilitated urea permeability in rat terminal IMCDs in vivo.
The terminal IMCD is generally thought to express only V 2 receptors (5, 6), although one study did find evidence for V 1a receptors by RT-PCR (22) . Previous studies showed that vasopressin stimulates urea permeability in perfused terminal IMCDs via the V 2 receptor by showing that dDAVP, a selective V 2 agonist, mimics the effect of vasopressin (21) . The present study shows that dDAVP also mimics the effect of vasopressin to increase UT-A1 phosphorylation.
Plasma vasopressin levels generally range between 10 Ϫ11 and 10 Ϫ10 M (4). These levels of vasopressin stimulate cAMP production in microdissected rat IMCDs (21). However, higher vasopressin levels (10 Ϫ8 -10 Ϫ7 M) stimulate substantially higher levels of cAMP production (21) and UT-A1 phosphorylation (present study). We chose to use 10 Ϫ8 M vasopressin in the present experiments because this concentration 1) resulted in a maximal rate of cAMP accumulation (21); 2) has been used in a large number of the perfused tubule measurements of urea permeability (reviewed in Ref. 18); and 3) provided an optimal signal-to-noise for assessing inhibition of the PKA pathway. Although this vasopressin concentration is higher than that found in systemic plasma, vasa recta vasopressin levels could be higher than plasma levels due to countercurrent multiplication. Because terminal IMCDs are exposed to vasa recta rather than systemic plasma, it is possible that these higher vasopressin concentrations may be physiological in the deepest portions of the inner medulla.
We also found that inhibitors of PKA reduce both the vasopressin-stimulated and basal levels of phosphorylation of UT-A1. This result strongly suggests that PKA is phosphorylating UT-A1, both basally and in response to vasopressin stimulation. The reduction in basal phosphorylation by H-89 suggests that adenylyl cyclase may be constitutively phosphorylating UT-A1 in the IMCD. However, we cannot determine from the present studies whether PKA is directly phosphorylating UT-A1 or whether it phosphorylates UT-A1 indirectly by activating another kinase (or kinases), which then phosphorylates UT-A1.
PKA typically results in the phosphorylation of serine or threonine residues. The increase in UT-A1 phosphorylation by okadaic acid or calyculin is consistent with a serine or threonine phosphorylation site (1, 3, 9) , and we showed that vasopressin does not phosphorylate a tyrosine residue. Future studies will be needed to determine the residues in UT-A1 that are phosphorylated by vasopressin.
Finally, the present study suggests a mechanism by which two vasopressin-regulated transport processes, water and urea transport, can be independently regulated: 1) urea permeability is regulated primarily by phosphorylation of UT-A1; whereas 2) osmotic water permeability is regulated primarily by the regulated trafficking of AQP2, although phosphorylation of AQP2 is important for its insertion into the apical membrane and the formation of tetramers (10) . Atrial natriuretic factor inhibits vasopressin-stimulated osmotic water permeability, but not vasopressin-stimulated urea per- Fig. 7 . Calyculin and okadaic acid, inhibitors of protein phosphatases PP1 and PP2A, cause increased phosphorylation of UT-A1. After radiolabel loading for 3 h, either calyculin (5 or 50 nM) or okadaic acid (1 or 10 M) was added to the IMCD suspension for 15 min. IMCDs were processed and UT-A1 was immunoprecipitated as described in METHODS. An autoradiograph of the UT-A1 proteins from these samples is shown. Left: control IMCDs (ctrl) and IMCDs that received 5 or 50 nM calyculin. Middle: control IMCDs (Ctrl) and IMCDs that received 1 or 10 M okadaic acid. Right: densitometric analysis of calyculin (Caly; 50 nM, n ϭ 10, *P Ͻ 0.001) and okadaic acid (OA; 10 M, n ϭ 4, *P Ͻ 0.002) treatments, showing that inhibition of serine/ threonine phosphatases significant increases in UT-A1 phosphorylation. Fig. 8 . Phosphorylation of UT-A1 does not occur on tyrosine residues. Two identical IMCD suspensions were incubated with antibodies to UT-A1 and phosphotyrosine (p-Tyr)-containing proteins (PY-20). Immunoprecipitated proteins were separated by SDS-PAGE and blotted to polyvinylidene difluoride membranes. Each blot contains, from left to right, UT-A1 immunoprecipitate, preimmunoprecipitation IMCD lysate, and PY-20 immunoprecipitate. Blots were probed with antibodies to UT-A1 (A) and PY-20 (B), the antibody that recognizes p-Tyr-containing proteins. Anti-UT-A1 did not recognize any proteins in the p-Tyr-protein pool, and PY-20 did not recognize immunoprecipitated UT-A1. meability, in perfused rat terminal IMCDs (17) . This result could be explained if atrial natriuretic factor were to affect the trafficking of AQP2, but had no effect on phosphorylation, in response to vasopressin. Future studies will be needed to test this hypothesis.
